<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04492150</url>
  </required_header>
  <id_info>
    <org_study_id>4018</org_study_id>
    <nct_id>NCT04492150</nct_id>
  </id_info>
  <brief_title>Effect of Glucose 5% on Labor Length</brief_title>
  <official_title>The Effect of Adding Parenteral Dextrose Solution During Induction of Labor on Total Labor Length Among Multiparous Women in Ismailia, Egypt: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suez Canal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suez Canal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of labor, is one of the most common obstetric procedures done routinely in modern&#xD;
      obstetrics. For example, in USA, 23% of pregnant women in 2012 (about 1 million) underwent an&#xD;
      induction of labor. However, accurate data about percentage of women undergoing induction of&#xD;
      labor in Egypt is not accurately known.&#xD;
&#xD;
      One of the recent research era in current obstetrics is the optimal intravenous (IV)&#xD;
      hydration of the pregnant women in labor.Current evidences available in our hands, suggest&#xD;
      that maternal hydration appears to fasten labor progress and enhance the action of oxytocin,&#xD;
      if the later is used for augmentation. However, the addition of glucose supplementation to&#xD;
      this IV hydration to enhance uterine contraction, as a matter of safety and efficacy, is&#xD;
      controversial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">October 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the duration of labor</measure>
    <time_frame>24 hours</time_frame>
    <description>the duration from the beginning of active labor (cervical exam between 3 and 5 cm with regular uterine contractions) to fetal delivery, reported in minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of cesarean sections</measure>
    <time_frame>24 hours</time_frame>
    <description>the number of cases delivered by cesarean section</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women who will receive 250 mL/hour of dextrose 5% with normal saline in a 1:1 ratio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>women who will receive 250 mL/hour of normal saline for the whole duration of induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose 5%/Nacl 0.3% Inj_#3</intervention_name>
    <description>250 mL/hour of dextrose 5% intravenous drip</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>250 mL/hour of normal saline intravenous drip</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (&gt;18 years) multiparous women&#xD;
&#xD;
          -  Late Term Pregnancy ( gestational Age Between 40-42 weeks)&#xD;
&#xD;
          -  Uncomplicated singleton pregnancy with cephalic presentation.&#xD;
&#xD;
          -  Favorable cervix for induction (Bishop score&lt;6) without ruptured membranes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with chronic diseases or complicated pregnancy; gestational and pre gestational&#xD;
             ( type 1 &amp; 2)diabetes, preeclampsia and\or renal and\or maternal heart diseases.&#xD;
&#xD;
          -  Non-cephalic presentations, multiple pregnancies, or cervix unfavorable for induction.&#xD;
&#xD;
          -  Other indications for cesarean delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zakia M Ibraheim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor of Gynecology and Obstetrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariam L Mohammed, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor of Gynecology and Obstetrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanan M Ghoneim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor of Gynecology and Obstetrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M Abbas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor of Gynecology and Obstetrics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salwa H Tammam, M. B. B. Ch</last_name>
    <phone>00201012869258</phone>
    <email>Dr.salwa.hussein.tammam@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Suez canal University</name>
      <address>
        <city>Ismailia</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salwa Hussein, MMBCh</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Suez Canal University</investigator_affiliation>
    <investigator_full_name>Salwa Hussein Ismaeil Tammam</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

